Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study.
Clostridium difficile infection
hematopoietic stem cell transplantation
solid organ transplantation
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
18
10
2021
received:
04
07
2021
accepted:
06
11
2021
pubmed:
26
11
2021
medline:
10
2
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality in recipients of solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). In retrospective single center analyses, severe disease and relapse are common. We undertook an international, prospective cohort study to estimate the response to physician determined antibiotic treatment for CDI in patients with SOT and HSCT. Adults with a first episode of CDI within the first 2 years of SOT or HSCT were enrolled. Demographics, comorbidities, and medication history were collected, and over 90 days of follow-up clinical cure, recurrences, and complications were assessed. Logistic regression was used to study associations of baseline predictors of clinical cure and recurrence. Odds ratios (ORs) and 95% confidence intervals (CIs) are cited. A total of 132 patients, 81 SOT and 51 HSCT (32 allogeneic), were enrolled with a median age of 56 years; 82 (62%) were males and 128 (97%) were hospitalized at enrollment. One hundred and six (80.3%) were diagnosed by DNA assay. CDI occurred at a median of 20 days post-transplant (interquartile range, IQR: 6-133). One hundred and eight patients (81.8%) were on proton pump inhibitors; 126 patients (95.5%) received antibiotics within the 6 weeks before CDI. The most common initial CDI treatments prescribed, on or shortly before enrollment, were oral vancomycin alone (50%) and metronidazole alone (36%). Eighty-three percent (95% CI: 76, 89) of patients had clinical cure; 18% (95% CI: 12, 27) of patients had recurrent CDI; global clinical cure occurred in 65.2%. Of the 11 patients who died, two (1.5% of total) were related to CDI. In multivariable logistic regression analyses, the type of initial treatment was associated with clinical cure (p = .009) and recurrence (p = .014). A history of cytomegalovirus (CMV) after transplant was associated with increased risk of recurrence (44% with versus 13% without CMV history; OR: 5.7, 95% CI: 1.5, 21.3; p = .01). Among adults who develop CDI after SOT or HSCT, despite their immunosuppressed state, the percentage with clinical cure was high and the percentage with recurrence was low. Clinical cure and recurrence varied by type of initial treatment, and CMV viremia/disease was associated with an increased risk of recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Clostridioides difficile infection (CDI) is a significant cause of morbidity and mortality in recipients of solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). In retrospective single center analyses, severe disease and relapse are common. We undertook an international, prospective cohort study to estimate the response to physician determined antibiotic treatment for CDI in patients with SOT and HSCT.
METHODS
METHODS
Adults with a first episode of CDI within the first 2 years of SOT or HSCT were enrolled. Demographics, comorbidities, and medication history were collected, and over 90 days of follow-up clinical cure, recurrences, and complications were assessed. Logistic regression was used to study associations of baseline predictors of clinical cure and recurrence. Odds ratios (ORs) and 95% confidence intervals (CIs) are cited.
RESULTS
RESULTS
A total of 132 patients, 81 SOT and 51 HSCT (32 allogeneic), were enrolled with a median age of 56 years; 82 (62%) were males and 128 (97%) were hospitalized at enrollment. One hundred and six (80.3%) were diagnosed by DNA assay. CDI occurred at a median of 20 days post-transplant (interquartile range, IQR: 6-133). One hundred and eight patients (81.8%) were on proton pump inhibitors; 126 patients (95.5%) received antibiotics within the 6 weeks before CDI. The most common initial CDI treatments prescribed, on or shortly before enrollment, were oral vancomycin alone (50%) and metronidazole alone (36%). Eighty-three percent (95% CI: 76, 89) of patients had clinical cure; 18% (95% CI: 12, 27) of patients had recurrent CDI; global clinical cure occurred in 65.2%. Of the 11 patients who died, two (1.5% of total) were related to CDI. In multivariable logistic regression analyses, the type of initial treatment was associated with clinical cure (p = .009) and recurrence (p = .014). A history of cytomegalovirus (CMV) after transplant was associated with increased risk of recurrence (44% with versus 13% without CMV history; OR: 5.7, 95% CI: 1.5, 21.3; p = .01).
CONCLUSIONS
CONCLUSIONS
Among adults who develop CDI after SOT or HSCT, despite their immunosuppressed state, the percentage with clinical cure was high and the percentage with recurrence was low. Clinical cure and recurrence varied by type of initial treatment, and CMV viremia/disease was associated with an increased risk of recurrence.
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13770Subventions
Organisme : Astellas Pharma Europe Ltd.
Organisme : Merck Sharp and Dohme
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Guh AY, Mu Y, Winston LG, et al. Trends in U.S. Burden of Clostridioides difficile infection and outcomes. NEJM. 2020;382:1320-1330.
Suetens C, Latour K, Kärki T, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. Euro Surveill. 2018;23(46):1800516.
Paudel S, Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS ONE. 2015;10(4):e0124483.
Ilett EE, Helleberg M, Reekie J, et al. Incidence rates and risk factors of Clostridioides difficile infection in solid organ and hematopoietic stem cell transplant recipients. Open Forum Infect Dis. 2019;6(4):ofz086.
Schluger A, Rosenblatt R, Knotts R, Verna EC, Pereira MR. Clostridioides difficile infection and recurrence among 2622 solid organ transplant recipients. Transpl Infect Dis. 2019;21:e13184.
Tsapepas DS, Martin ST, Miao J, et al. Clostridium difficile infection, a descriptive analysis of solid organ transplant recipients at a single center. Diagnostic Micro Infect Dis. 2015;81:299-304.
Spinner ML, Stephany BR, Cerrato PM, Lam SW, Neuner EA, Patel KS. Risk factors associated with Clostridium difficile infection in kidney transplant recipients. Transpl Infect Dis. 2018;20:e12918.
Zacharioudakis IM, Ziakas PD, Mylonakis E. Clostridium difficile infection in the hematopoietic unit: a meta-analysis of published studies. Biol Blood Marrow Transplant. 2014;20:1650-1654.
Shah NN, McClellan W, Flowers CR, et al. Evaluating risk factors for Clostridium difficile infections in stem cell transplant recipients: a national study. Infect Control Hosp Epidemiol. 2017;38:651-657.
Aldrete SD, Kraft CS, Magee MJ, et al. Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period. Transpl Infect Dis. 2017;19:e12649.
Donnelly JP, Wang HE, Locke JE, Mannon RB, Safford MM, Baddley JW. Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant. 2015;15:2970-2977.
Mullane KM, Dubberke ER. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: guidelines from the American Society of Transplantation Community of Practice. Clin Transplant. 2019;33:e13564.
Nanayakkara D, Nanda N. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant. 2017;22:314-319.
Huang AM, Marini BL, Frame D, Aronoff DM, Nagel JL. Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2014;16:744-750.
Dubberke ER, Reske KA, Olsen MA, et al. Epidemiology and outcomes of Clostridium difficile infection in allogeneic hematopoietic cell and lung transplant recipients. Transpl Infect Dis. 2018;20:e12855.
Bruminhent J, Wang Z-X, Hu C, et al. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1329-1334.
Cho J, Seville MT, Khanna S, Pardi DS, Sampathkumar P, Kashyap PC. Screening for Clostridium difficile colonization on admission to a hematopoietic stem cell transplant unit may reduce hospital-acquired C difficile infection. Am J Infect Control. 2018;46:459-461.
Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73:e1029-e1044.
Ganetsky A, Han JH, Hughes ME, et al. Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Clin Infect Dis. 2019;68:2003-2009.
Amberge S, Kramer M, Schröttner P, et al. Clostridium difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome. Bone Marrow Transplant. 2020;55:367-375.
Bhutani D, Jaiyeoba C, Kim S, et al. Relationship between Clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2019;54:164-167.
Cusini A, Béguelin C, Stampf S, et al. Clostridium difficile infection is associated with graft loss in solid organ transplant recipients. Am J Transplant. 2018;18:1745-1754.
Li GJ, Trac J, Husain S, Famure O, Li Y, Kim J. Incidence, risk factors, and outcomes of Clostridium difficile infections in kidney transplant recipients. Transplantation. 2018;102:1576-1581.
Mittal C, Hassan S, Arshad S, et al. Clostridium difficile infection in liver transplant recipients: a retrospective study of rates, risk factors and outcomes. Am J Transplant. 2014;14:1901-1907.
Sullivan S, Weinberg A, Rana M, Patel G, Huprikar S. The epidemiology and clinical features of Clostridium difficile infection in liver transplant recipients. Transplantation. 2016;100:1939-1943.
Lavallée C, Labbé A-C, Talbot J-D, et al. Risk factors for the development of Clostridium difficile infection in adult allogeneic hematopoietic stem cell transplant recipients: a single-center study in Québec, Canada. Transpl Infect Dis. 2017;19:e12648.
Muñoz P, Giannella M, Alcalá L, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J Heart Lung Transplant. 2007;26:907-914.
Florescu DF, Kalil AC, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant. 2013;13:2601-2610.